Oviva’s team is a coalition of rigorous scientists, translational biologists, experienced drugmakers and creative problem-solvers passionate about building medicines that will transform women’s health and well-being.
Co-Founder, CEO and Board Director
Read full bio
.svg)
Dr. Daisy Robinton is passionate about elevating women’s health and challenging the status quo of female aging. She launched Oviva Therapeutics with the vision to tackle aging in women while addressing the historic gender disparity in biomedical research and healthcare. Dr. Robinton completed her PhD in Human Biology and Translational Medicine at Harvard University and landed on the Forbes 30 Under 30 list for her scientific discoveries. Her writing has been published in periodicals such as Nature, Vanity Fair and NEO.LIFE. Her work as a molecular biologist, writer, public speaker, and lifestyle & fitness model, contribute to the unique lens with which she examines the intersection of science and culture.
Co-Founder & Scientific Advisor
Read full bio
Dr. Pépin is an Associate Professor in the Department of Surgery at Harvard Medical School, an Associate Molecular Biologist at the Massachusetts General Hospital (MGH), and the Associate Director of the Pediatric Surgical Research Laboratories of MGH. Dr. Pépin is a reproductive biologist with expertise in ovarian biology. His research interests include both basic reproductive developmental research and its application to women’s health. In particular, Dr. Pépin has investigated the role of MIS in female reproduction in the context of ovarian function and disease. Together with Dr. Donahoe, he has described the contraceptive effect of superphysiological MIS in several animal models, examined the mechanisms of follicular quiescence, and is investigating clinical applications in contraception, assisted reproduction, oncofertility, and aging.
Co-Founder & Scientific Advisor
Read full bio
Patricia K. Donahoe is Director Pediatric Surgical Research Laboratories, Chief Emerita Pediatric Surgical Services MGH, and Marshall K. Bartlett Professor of Surgery Harvard Medical School. Her research focuses on Müllerian Inhibiting Substance in reproductive development and as a potential therapeutic for ovarian cancers, and recently, with David Pepin PhD, as an agent to enhance fertility, contraception and ovarian protection. An Associate Member of the Broad Institute and Faculty of the Harvard Stem Cell Institute and the Center for Human Genomic Research at MGH, Dr. Donahoe has trained >100 fellows and published >300 peer-reviewed articles. She is a member of the National Academy of Sciences (1999), National Academy of Medicine (1991), National Academy of Inventors (2021), and the American Academy of Arts & Sciences (1987)
Co-Founder, CEO and Board Director
Read full bio
Dr. Daisy Robinton is passionate about elevating women’s health and challenging the status quo of female aging. She launched Oviva Therapeutics with the vision to tackle aging in women while addressing the historic gender disparity in biomedical research and healthcare. Dr. Robinton completed her PhD in Human Biology and Translational Medicine at Harvard University and landed on the Forbes 30 Under 30 list for her scientific discoveries. Her writing has been published in periodicals such as Nature, Vanity Fair and NEO.LIFE. Her work as a molecular biologist, writer, public speaker, and lifestyle & fitness model, contribute to the unique lens with which she examines the intersection of science and culture.
Board Director
Read full bio
James Peyer is the Chief Executive Officer and Founder of Cambrian Bio. He also holds multiple board and executive roles across Cambrian’s pipeline. He has spent his entire life dedicated to the mission of finding ways of preventing people from getting diseases like cancer and Alzheimer’s instead of waiting for people to get sick. James was previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm, investing across the US and Europe. Prior to Apollo, James was a biotech R&D specialist at the New York office of McKinsey & Company, serving major pharmaceutical clients. He earned his PhD in stem cell biology at University of Texas Southwestern Medical Center as a National Science Foundation Fellow and received his B.A. with special honors from the University of Chicago.
.png)
Board Director
Read full bio
Mark Nuttall is the Executive Vice President of Business Development at Cambrian Bio. He was previously Chief Business Officer for Kintai Therapeutics/Senda Biosciences, a Flagship Pioneering company, & Kymera Therapeutics (KYMR). Mark has held senior roles in business development (BD) functions at several large pharmaceutical companies. He was Vice President and Head of BD & Licensing for core therapeutic franchises at Sanofi Genzyme. At Johnson & Johnson, he led neuroscience BD and was responsible for leading a team that transformed J&J’s CNS portfolio. Mark began his career in the healthcare industry in R&D at GlaxoSmithKline and AstraZeneca. He has a B.Sc. in biochemistry from the University College of Wales in Cardiff and a Ph.D. in molecular and cell biology from the University of Aberdeen, Scotland.
Board Observer
Read full bio
As Strategic Innovation Leader, Seema Basu, PhD, directs the strategy for open innovation and strategic alliances. She leads a team responsible for enabling strategic corporate alliances and new initiatives, such as the Innovation Fellows Program for collaboration with industry. Additionally, team manages licensing and partnering of IP portfolios from Regenerative Medicine, Ragon Institute of MGH, MIT and Harvard, and MGH Center for Global Health. She represents Mass General Brigham at numerous national and regional organizations. She has more than a decade of deep experience in industry-academic collaborations and business development & licensing at Mass General Brigham and Harvard and a successful laboratory career at Parke-Davis and Albany Medical Center. She earned her PhD from the University of Notre Dame.
Director of R&D
Read full bio
Lorna Fiedler is Director of R&D at Oviva. She has over 20 years’ experience in disease biology and drug discovery from concept to late-stage preclinical development. She is passionate about translating innovative science into patient benefit and has held leadership positions across several therapeutic areas, and managed development programmes for biologic, small molecule and RNAi therapeutics. As R&D Director and Project Manager at Cambrian Biopharma, she led three Candidate to IND phase programmes. She was responsible for defining R&D strategies and integrating nonclinical, CMC, clinical planning and regulatory workstreams, working with multiple stakeholders to drive successful delivery. She also led a diligence task force to make recommendations to senior management on the path to commercialization for one of these programmes. Previously as Principal Scientist and Program Manager at e-therapeutics, she established a project management framework and coordinated cross-disciplinary efforts to establish new hepatocyte and RNAi based platforms. She also led the target-indication assessment team and was responsible for developing detailed project proposals and pitching recommendations to senior management. She was previously Associate Director for Research at Oxstem, an Oxford University spin-out focused on regenerative medicine. Lorna has held postdoctoral positions at University College London, Imperial College London, where she developed a cardioprotective small molecule, Oxford University and Duke-NUS Medical School in Singapore. Her research has been published in leading journals and featured in Fierce Biotech. She has a PhD in Cell and Extracellular Matrix Biology from Cardiff University and is an Associate Editor for Bioscience Reports.
Fellow
Read full bio
Nicole Lustgarten Guahmich, Ph.D. is a reproductive biologist and clinical embryologist with a passion for applying clinical research to develop technologies that improve access to care in women's reproductive sciences and infertility. Dr. Lustgarten Guahmich completed her graduate degree at the Weill Cornel Graduate School for Medical Science where she focused on unraveling the intricacies of uterine vascular growth during early pregnancy. Following, she joined the Center for Reproductive Medicine at Weill Cornell as a postdoctoral researcher studying the mechanisms that lead to cellular recruitment and oocyte activation within the human ovary.
Scientific Advisor
Dr. Thompson is a Professor in the Department of Molecular and Cellular Biosciences at the University of Cincinnati, College of Medicine. He studies the structure and function of several TGFb family members, including AMH, where his laboratory was the first to determine the structure of AMH bound to the type II receptor, AMHR2. Dr. Thompson received his PhD from the Biochemistry Department at the University of Wisconsin Madison and completed a post-doctoral fellowship at Northwestern University.
Principal Consultant
Dr Angeles Escarti-Nebot is a Head of Nonclinical and Principal Consultant at Scendea (https://www.scendea.com/) with experience in the initiation, management and execution of regulatory projects from early development to marketing authorisation. Angeles has previously held positions in Parexel and PhamaLex and her areas of expertise include regulatory strategy, non-clinical and quality development programs for the EU and US jurisdictions. Angeles has a strong scientific background with more than seven years’ experience on biotechnology research and more than 10 years’ experience in a regulatory environment. Angeles holds a PhD in molecular and cellular biology, BA in Pharmacy, MS in Clinical Genetics and MS in Neuropharmacology.
Business and Strategy Advisor
Mr. Goldberg is a proven leader of several biotech companies, and currently serves as Executive Chair for Stradefy Bioscienes. Prior to that he was CEO of Aeglea Biotherapeutics, CEO of Immunitas, and founding Chief Operating Officer at Akcea where he grew a team of 2 employees to over 250 in multiple geographies. Mr. Goldberg played a significant role in the company's initial public offering, fundraising activities, business development, and the global launch of two rare disease drugs. Prior to Akcea, he was Vice President of Business Operations at Proteostasis Therapeutics, a rare disease company. He has also held roles of increasing responsibility at Genzyme, where he led teams through product development and global launches across multiple therapeutic areas. Mr. Goldberg has an MBA and a MS in Chemical Engineering from the Massachusetts Institute of Technology (MIT), and a B.S. in Chemical Engineering from Cornell University.
Clinical and Translational Advisor
Emre Seli, MD, is Professor of Obstetrics, Gynecology & Reproductive Sciences and Medical Director of Yale Reproductive Endocrinology & Infertility Division. His laboratory characterized the mechanisms regulating translational activation of gene expression in the oocyte. Dr. Seli and his colleagues also made contributions to our understanding of oocyte and embryo competence in IVF and the potential role of non-invasive diagnostic technologies in this context. Dr. Seli is the recipient of many National Institutes of Health (NIH) and pharmaceutical industry-sponsored research grants. He published more than 150 scientific articles and edited five books including the 9th edition of “Speroff’s Clinical Gynecologic Endocrinology and Infertility“. Dr. Seli’s current research focuses on determinants of oocyte and embryo health and mechanisms of ovarian aging.
Clinical Advisor
Mary Morris, MD, PhD, is the Medical Director of the Oncofertility Clinic and the Medical Director of the Third-Party Reproduction Program in the Reproductive Endocrinology and Infertility Division of the Department of Obstetrics and Gynecology at Massachusetts General Hospital. She is an Assistant Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School. Her primary research interests include exploring novel approaches to fertility preservation in those diagnosed with cancer and understanding clinical outcomes for women with hereditary cancer syndromes.
Scientific Advisor
Dr. Zelinski is a Professor in the Division of Reproductive & Developmental Sciences at the Oregon National Primate Research Center, and in the Department of Obstetrics & Gynecology at OHSU. Dr. Zelinski studies the basic mechanisms underlying the development, function and aging of primate ovarian follicles and conducts translational research in women’s reproductive health. She has 30 years of experience using nonhuman primate models of infertility, contraception and assisted reproductive technologies. She has received continuous funding from the NIH since 1998 & several awards from the American Society for Reproductive Medicine. She has published numerous peer-reviewed articles and served as Secretary, Program Chair and on the Board of Directors of the Society for the Study of Reproduction, from which she received the Distinguished Service Award.
Clinical and Translational Advisor
Samira Addo M.D., FRCOG, has more than 20 years of experience in the Biopharmaceutical Industry and expertise in Reproductive Medicine and Women’s Health. She has served in various leadership roles within Translational Medicine and Global R&D at Merck/MSD and Ferring. Dr Addo has demonstrated multi-disciplinary skills to integrate translational strategies and optimize lead candidates through preclinical to proof of concept for advancement to clinical development. Dr Addo received MBChB from the University of Ghana and continued her clinical internship at University College Hospital, London where she completed the postgraduate qualification in Obstetrics and Gynaecology. Dr Addo is an elected Fellow of the Royal College of Obstetricians & Gynaecologists, UK & an elected Governor to the Council of Governors for Cambridge University Hospitals NHS Foundation Trust.
.svg)
.svg)